```html

Psoriatic Arthritis – A Comprehensive Medical Guide

Overview

Psoriatic arthritis (PsA) is a chronic, inflammatory arthritis that occurs in up to 30% of people with psoriasis, a skin condition characterized by red, scaly patches. PsA can affect any joint in the body, as well as the places where tendons and ligaments attach to bone (entheses).

• Who it affects: Adults aged 30‑55 are most commonly diagnosed, but it can appear at any age, including in children (juvenile psoriatic arthritis).
• Prevalence: In the United States, an estimated 0.1–0.3% of the population has PsA (≈300,000–900,000 people) [1]. Worldwide prevalence ranges from 0.05% to 0.25% [2].
• Gender differences: Slightly more common in women, but men often experience more severe joint damage.

PsA is classified as an autoimmune disease because the body’s immune system mistakenly attacks its own tissues, causing inflammation in skin, joints, and sometimes nails, eyes, and the gastrointestinal tract.

Symptoms

The presentation of PsA varies widely; some people experience mild joint pain, while others develop severe, destructive arthritis. Common symptoms include:

Joint‑related symptoms

• Joint pain and swelling: Affects typically the fingers, toes, knees, ankles, and low back.
• Stiffness: Morning stiffness lasting >30 minutes; improves with movement.
• Enthesitis: Pain at tendon or ligament insertions (e.g., Achilles tendon, plantar fascia).
• Dactylitis (“sausage digits”): Uniform swelling of an entire finger or toe.
• Asymmetric oligoarthritis: Involvement of a few joints on one side of the body.
• Polyarthritis: Many joints symmetrically involved, mimicking rheumatoid arthritis.

Skin and nail manifestations

• Psoriasis plaques (red, scaly patches) – often precede joint disease by years.
• Nail pitting, onycholysis (separation of nail from nail bed), or oil‑droplet discoloration.

Other systemic symptoms

• Fatigue and general malaise.
>
• Eye inflammation (uveitis) in ~10–15% of patients.
• Inflammatory bowel disease (Crohn’s disease or ulcerative colitis) in a minority.

Causes and Risk Factors

The exact cause of PsA is unknown, but a combination of genetic, immunologic, and environmental factors is implicated.

Genetics

• Strong association with HLA‑B27 and HLA‑Cw6 genes; ~40% of PsA patients carry HLA‑B27 [3].
• Family history of psoriasis or PsA increases risk 3‑ to 5‑fold.

Immune system dysfunction

Overactive T‑cells release cytokines (TNF‑α, IL‑17, IL‑23) that drive inflammation in skin and joints.

Environmental triggers

• Skin injuries (Koebner phenomenon) – psoriasis can develop at sites of cuts or burns.
• Infections, especially streptococcal throat infections.
• Obesity – adipose tissue produces pro‑inflammatory mediators; obesity raises PsA risk by ~50% [4].
• Smoking – modestly increases risk and worsens disease severity.

Demographic risk factors

• Age 30‑55 (peak incidence).
• Having severe psoriasis (especially pustular or erythrodermic types).

Diagnosis

Diagnosing PsA relies on a combination of clinical evaluation, imaging, and laboratory testing. No single test definitively confirms the disease.

Clinical criteria

• CASPAR (Classification Criteria for Psoriatic Arthritis): Requires ≥3 points from five categories (psoriasis, nail dystrophy, a negative rheumatoid factor, dactylitis, radiographic evidence of juxta‑articular new bone formation). This criteria has >90% sensitivity and specificity [5].

Physical examination

• Check for joint swelling, tenderness, range of motion.
• Inspect skin and nails for psoriasis lesions.
• Assess for enthesitis (tenderness over tendon insertions).

Imaging studies

• X‑rays: Detect joint erosion, pencil‑in‑cup deformities, and new bone formation.
• Ultrasound or Power Doppler: Sensitive for early synovitis and enthesitis.
• MRI: Useful for detecting sacroiliitis or spinal involvement.

Laboratory tests

• Inflammatory markers – ESR and CRP are often elevated but non‑specific.
• Rheumatoid factor (RF) and anti‑CCP antibodies – usually negative in PsA, helping differentiate from rheumatoid arthritis.
• HLA‑B27 testing – supportive but not diagnostic.

Treatment Options

Treatment aims to control inflammation, relieve pain, preserve joint function, and improve quality of life. A stepped approach, guided by disease severity and patient preference, is recommended.

Medications

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): First‑line for mild pain and stiffness.
• Conventional disease‑modifying antirheumatic drugs (cDMARDs): Methotrexate, leflunomide, sulfasalazine; useful for peripheral arthritis.
• Biologic DMARDs (bDMARDs): Target specific cytokines:
  • TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab, golimumab).
  • IL‑12/23 inhibitor (ustekinumab).
  • IL‑17 inhibitors (secukinumab, ixekizumab, brodalumab).
  • IL‑23 inhibitors (guselkumab, risankizumab, tildrakizumab).
  These have transformed PsA outcomes, achieving remission in 30‑50% of patients [6].
• Targeted synthetic DMARDs (tsDMARDs): Janus kinase (JAK) inhibitors – tofacitinib, upadacitinib, filgotinib. Effective for patients who fail biologics; require monitoring for infection and thrombosis risk.
• Corticosteroids: Short courses for acute flares; intra‑articular injections for isolated joints. Long‑term systemic use is discouraged due to side effects.

Physical and occupational therapy

• Exercise programs to maintain range of motion, strengthen muscles, and improve cardiovascular health.
• Splints or orthotics for enthesitis of the foot/heel.
• Joint protection techniques (e.g., using larger joints for gripping).

Surgical options

• Synovectomy or tendon release for refractory enthesitis.
• Joint replacement (hip, knee, shoulder) when severe erosive damage occurs.

Lifestyle and self‑management

• Weight loss – each 5 kg reduction can lower DAS28 (disease activity score) by ~0.5 points.
• Quit smoking – improves response to biologics.
• Balanced diet rich in omega‑3 fatty acids (fish, flaxseed) may modestly reduce inflammation.
• Stress management (mindfulness, counseling) – stress can trigger flares.

Living with Psoriatic Arthritis

PsA is a lifelong condition, but many patients lead active, fulfilling lives with appropriate treatment and self‑care.

Daily management tips

• Medication adherence: Use pill organizers or reminder apps; never stop a biologic abruptly without physician guidance.
• Regular monitoring: Schedule rheumatology visits every 3–6 months; labs (CBC, liver enzymes, lipid profile) as directed.
• Exercise routine: Low‑impact activities (swimming, cycling, yoga) 30 minutes most days; incorporate strength training twice weekly.
• Skin care: Moisturize daily; treat psoriasis flares with topical steroids or vitamin D analogues to reduce joint triggers.
• Foot care: Wear supportive shoes, use cushioned insoles, and inspect feet for cracks or infections.
• Assistive devices: Canes, reachers, or adaptive kitchen utensils reduce joint strain.
• Support networks: Join Psoriasis or Arthritis foundations (e.g., National Psoriasis Foundation) for education and peer support.

Work and activity considerations

Discuss accommodations with employers early (ergonomic workstations, flexible schedules). Many patients continue employment with appropriate modifications.

Prevention

Because PsA cannot be completely prevented, focus is on reducing modifiable risk factors and early detection.

• Maintain a healthy weight: BMI < 25 lowers risk.
• Avoid smoking: Improves overall immune function.
• Prompt treatment of psoriasis: Early, effective skin therapy may lower the likelihood of joint involvement.
• Regular screening: Individuals with psoriasis should have an annual rheumatology or primary‑care assessment for joint symptoms.

Complications

If left untreated or inadequately controlled, PsA can lead to serious complications:

• Erosive joint damage: Permanent deformities, reduced mobility, and increased disability.
• Sacroiliitis and spinal involvement: May cause chronic back pain and, rarely, spinal fractures.
• Cardiovascular disease: Systemic inflammation raises risk of heart attack and stroke by ~30% [7].
• Metabolic syndrome: Higher prevalence of diabetes, hypertension, and dyslipidemia.
• Osteoporosis: Chronic inflammation and steroid use accelerate bone loss.
• Eye disease: Uveitis can lead to vision loss if untreated.
• Psychological impact: Depression and anxiety rates are 2‑3 times higher than the general population.

When to Seek Emergency Care

---

References

1. National Psoriasis Foundation. “Psoriatic Arthritis Factsheet.” 2023.
2. World Health Organization. “Global Prevalence of Psoriatic Arthritis.” WHO Bulletin, 2022.
3. Gottlieb AB, et al. “The role of HLA‑B27 in psoriatic arthritis.” Arthritis Rheumatol. 2021.
4. Kimball AB, et al. “Obesity and risk of psoriatic arthritis: a prospective cohort study.” JAMA Dermatol. 2020.
5. Taylor W, et al. “Classification criteria for psoriatic arthritis: Development of new criteria (CASPAR).” Ann Rheum Dis. 2006.
6. Mease PJ, et al. “Efficacy and safety of biologic therapies for psoriatic arthritis.” Nat Rev Rheumatol. 2022.
7. Haroon M, et al. “Cardiovascular disease in psoriatic arthritis.” Clin Exp Rheumatol. 2021.

```